Johnson & Johnson (NYSE:JNJ) Shares Sold by Winslow Asset Management Inc.

Winslow Asset Management Inc. cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.3% during the 3rd quarter, Holdings Channel.com reports. The firm owned 30,954 shares of the company’s stock after selling 94 shares during the quarter. Winslow Asset Management Inc.’s holdings in Johnson & Johnson were worth $5,016,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in JNJ. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Johnson & Johnson during the first quarter worth $765,000. Empowered Funds LLC raised its stake in Johnson & Johnson by 46.7% during the first quarter. Empowered Funds LLC now owns 101,237 shares of the company’s stock worth $16,015,000 after acquiring an additional 32,244 shares during the period. Concurrent Investment Advisors LLC boosted its stake in Johnson & Johnson by 0.8% in the first quarter. Concurrent Investment Advisors LLC now owns 72,368 shares of the company’s stock valued at $11,448,000 after acquiring an additional 608 shares during the period. Bey Douglas LLC raised its position in shares of Johnson & Johnson by 4.6% during the 1st quarter. Bey Douglas LLC now owns 1,826 shares of the company’s stock worth $289,000 after purchasing an additional 81 shares during the period. Finally, Nixon Peabody Trust Co. increased its position in Johnson & Johnson by 4.6% in the first quarter. Nixon Peabody Trust Co. now owns 111,636 shares of the company’s stock worth $17,660,000 after buying an additional 4,942 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

JNJ opened at $152.64 on Wednesday. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $367.50 billion, a P/E ratio of 22.09, a PEG ratio of 2.75 and a beta of 0.53. The stock has a fifty day moving average of $162.39 and a 200-day moving average of $155.97.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the prior year, the business earned $2.66 EPS. Equities analysts forecast that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.25%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 71.78%.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. TD Securities lowered their price target on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Royal Bank of Canada raised their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Daiwa America cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Citigroup upped their target price on Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Finally, Sanford C. Bernstein boosted their price objective on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Seven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $175.00.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.